Estimating the Economically Justifiable Price of Limited-Duration Treatment with Donanemab for Early Symptomatic Alzheimer's Disease in the United States.
Donanemab
Alzheimer’s disease
Amyloid-targeting therapies
Cost-effectiveness
Economically justifiable price
Journal
Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818
Informations de publication
Date de publication:
18 Sep 2024
18 Sep 2024
Historique:
received:
28
05
2024
accepted:
19
07
2024
medline:
18
9
2024
pubmed:
18
9
2024
entrez:
18
9
2024
Statut:
aheadofprint
Résumé
The goal of this economic model is to estimate an economically justifiable price (EJP) for using donanemab for the treatment of early symptomatic Alzheimer's disease (AD) in the United States based on clinical data from the phase 3 TRAILBLAZER-ALZ 2 trial (NCT04437511). We adapted an AD Markov state-transition model developed by the Institute for Clinical and Economic Review to estimate the EJP for donanemab at different willingness-to-pay (WTP) thresholds from the health care system perspective and the societal perspective as co-base cases. Assuming a WTP threshold of $150,000 per quality-adjusted life-year (QALY) gained, the model estimates a 1-year (13-dose) EJP for donanemab of $80,538 from the health care system perspective and $91,126 from the societal perspective; at a WTP threshold of $100,000 per QALY gained, the model estimates a 1-year (13-dose) EJP for donanemab of $44,691 from the health care system perspective and $55,419 from the societal perspective. Mean total treatment costs per patient at the $150,000 per QALY gained EJP derived from the health care system perspective were estimated at $77,812 based on the average number of doses of donanemab patients received in the co-base case analysis. One-way sensitivity analysis (OWSA) indicated that treatment efficacy, disease severity at the time of treatment initiation, and duration of treatment effect were the main drivers of the potential EJP. Results from this modeling simulation informed by the TRAILBLAZER-ALZ 2 study support an EJP for limited-duration treatment with donanemab that exceeds per-dose list prices for currently available amyloid-targeting therapies, implying potentially lower lifetime costs and better value for money.
Identifiants
pubmed: 39292433
doi: 10.1007/s40120-024-00649-y
pii: 10.1007/s40120-024-00649-y
doi:
Banques de données
ClinicalTrials.gov
['NCT04437511']
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Alzheimer's Association. 2023 Alzheimer’s disease facts and figures. Alzheimers Dement. 2023;19(4):1598–695.
doi: 10.1002/alz.13016
Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14(4):535–62.
doi: 10.1016/j.jalz.2018.02.018
pubmed: 29653606
Biogen Inc. ADUHELM™ (aducanumab-avwa), US Prescribing Information. August 2023.
Eisai Inc. LEQEMBI (lecanemab-irmb) US Prescribing Information. July 2023.
Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10(3):362–77.
pubmed: 37357276
pmcid: 10313141
Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, et al. Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis. 2022;9(2):221–30.
pubmed: 35542993
pmcid: 9169517
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in early symptomatic Alzheimer’s disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512–27.
doi: 10.1001/jama.2023.13239
pubmed: 37459141
pmcid: 10352931
Boustani M, Doty EG, Garrison LP Jr, Smolen LJ, Belger M, Klein TM, et al. Assessing the cost-effectiveness of a hypothetical disease-modifying therapy with limited duration for the treatment of early symptomatic Alzheimer disease. Clin Ther. 2022;44(11):1449–62.
doi: 10.1016/j.clinthera.2022.09.008
pubmed: 36210219
Potashman M, Buessing M, Levitchi Benea M, Cummings J, Borson S, Pemberton-Ross P, Epstein AJ. Estimating Progression Rates Across the Spectrum of Alzheimer's Disease for Amyloid-Positive Individuals Using National Alzheimer's Coordinating Center Data. Neurol Ther. 2021;10(2):941–53. https://doi.org/10.1007/s40120-021-00272-1 .
Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–103.
doi: 10.1001/jama.2016.12195
pubmed: 27623463
Lin GA, Whittington MD, Wright A, Agboola F, Herron-Smith S, Pearson SD, Rind DM. Lecanemab for early Alzheimer’s disease: final evidence report. Institute for Clinical and Economic Review. 2023.
Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer’s disease. Neurology. 1999;52(6):1138–45.
doi: 10.1212/WNL.52.6.1138
pubmed: 10214734
Pontecorvo MJ, Lu M, Burnham SC, Schade AE, Dage JL, Shcherbinin S, et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: a secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022;79(12):1250–9.
doi: 10.1001/jamaneurol.2022.3392
pubmed: 36251300
pmcid: 9577883
Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, Weinstein MC. Health utilities in Alzheimer’s disease: a cross-sectional study of patients and caregivers. Med Care. 1999;37(1):27–32.
doi: 10.1097/00005650-199901000-00005
pubmed: 10413389
Mesterton J, Wimo A, By A, Langworth S, Winblad B, Jönsson L. Cross sectional observational study on the societal costs of Alzheimer’s disease. Curr Alzheimer Res. 2010;7(4):358–67.
doi: 10.2174/156720510791162430
pubmed: 19939223
Leibson CL, Long KH, Ransom JE, Roberts RO, Hass SL, Duhig AM, et al. Direct medical costs and source of cost differences across the spectrum of cognitive decline: a population-based study. Alzheimers Dement. 2015;11(8):917–32.
doi: 10.1016/j.jalz.2015.01.007
pubmed: 25858682
Administration on Aging. Costs of Care [Available from: https://acl.gov/ltc ]. Accessed 23 Dec 2020.
Robinson RL, Rentz DM, Andrews JS, Zagar A, Kim Y, Bruemmer V, et al. Costs of Early Stage Alzheimer’s Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US). J Alzheimers Dis. 2020;75(2):437–50.
doi: 10.3233/JAD-191212
pubmed: 32250304
pmcid: 7306889
Centers for Medicare & Medicaid Services (CMS). Physician Fee Schedule Search. 2023.
Economically Justifiable Price [online] York: York Health Economics Consortium; 2016 [Available from: http://www.yhec.co.uk/glossary/economically-justifiable-price/ . Accessed 6 May 2024.
Institute for Clinical and Economic Review. Value Assessment Framework 2023 [updated 25-Sep-2023]. Available from: https://icer.org/wp-content/uploads/2023/10/ICER_2023_VAF_For-Publication_101723.pdf . Accessed 26 June 2024.
Lakdawalla DN, Phelps CE. Health technology assessment with risk aversion in health. J Health Econ. 2020;72:102346.
doi: 10.1016/j.jhealeco.2020.102346
pubmed: 32592923
pmcid: 7402585
Potashman M, Levitchi Benea M, Gillis C, Gianinazzi M, Ikram MA, Maserejian N. PND59 Estimating the prevalence of Abeta-confirmed Alzheimer’s disease using a funnel-based approach. Value in Health. 2020;23(Supplement 2):S633–4.
doi: 10.1016/j.jval.2020.08.1384
Johnson RW. What is the lifetime risk of needing and receiving long-term services and supports. Office of the Assistant Secretary for Planning and Evaluation Washington, DC. 2019.
Eli Lilly and Co. Donanemab for the Treatment of Patients with Early Symptomatic Alzheimer's disease: Sponsor Briefing Document. In: Peripheral and Central Nervous System Drugs Advisory Committee. 2024. https://www.fda.gov/media/179167/download
US Food & Drug Administration, Combined FDA and applicant PCNS Drugs Advisory Committee briefing document. Peripheral and Central Nervous System Drugs Advisory Committee Meeting Online; 2020. https://www.fda.gov/media/179166/download
Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis. 2022;9(2):197–210.
pubmed: 35542991
Haeberlein SB, Gheuens S, Chen T, O'Gorman J, Von Rosenstiel P, Chiao P, et al. Aducanumab 36-month data from PRIME: A randomized, double-blind, placebo-controlled phase 1b study in patients with prodromal or mild Alzheimer's disease. In: Neurology Conference: 70th Annual Meeting of the American Academy of Neurology, AAN. 2018;90(15 Supplement 1).
Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–704.
doi: 10.1056/NEJMoa2100708
pubmed: 33720637
Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021;13(1):80.
doi: 10.1186/s13195-021-00813-8
pubmed: 33865446
pmcid: 8053280
Salloway S. Donanemab in early symptomatic Alzheimer’s disease: safety results from TRAILBLAZER-ALZ 2. Alzheimer's Association International Conference; July 16–20; Amsterdam, Netherlands; 2023.
Hansson O. Donanemab in Early Symptomatic Alzheimer’s Disease: Biomarker Results from TRAILBLAZER-ALZ 2. Alzheimer's Association International Conference; July 16–20; Amsterdam, Netherlands; 2023.
Chapleau M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD. The role of amyloid PET in imaging neurodegenerative disorders: a review. J Nucl Med. 2022;63(Supplement 1):13S-S19.
doi: 10.2967/jnumed.121.263195
pubmed: 35649652
pmcid: 9165727
Xu R, Insinga RP, Golden W, Hu XH. EuroQol (EQ-5D) health utility scores for patients with migraine. Qual Life Res. 2011;20(4):601–8.
doi: 10.1007/s11136-010-9783-5
pubmed: 21063786
US Bureau of Labor Statistics. Average hourly and weekly earnings of all employees on private nonfarm payrolls by industry sector, seasonally adjusted. 2022.
Centers for Medicare & Medicaid Services. Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431R) Decision Memo 2023 [updated Oct. 13, 2023]. Available from: https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=308 . Accessed 2 Nov 2023.
Sims JR. Donanemab in Early Symptomatic Alzheimer’s Disease: Clinical Efficacy Results from TRAILBLAZER-ALZ 2. Alzheimer's Association International Conference; 16–20 Jul 2023; Amsterdam, Netherlands; 2023.
Eli Lilly and Company. KINSULA (donanemab-azbt) US Prescribing Information. July 2024.
US Food & Drug Administration. Updated Public Participation Information: June 10, 2024: Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting Announcement 2024 [updated 18-Jun-2024]. Available from: https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-public-participation-information-june-10-2024-meeting-peripheral-and-central-nervous-system . Accessed 1 July 2024.
Wessels AM, Dennehy EB, Dowsett SA, Dickson SP, Hendrix SB. Meaningful clinical changes in Alzheimer disease measured with the iADRS and illustrated using the donanemab TRAILBLAZER-ALZ study findings. Neurol Clin Pract. 2023;13(2): e200127.
doi: 10.1212/CPJ.0000000000200127
pubmed: 36891463
pmcid: 9987204
Shcherbinin S, Evans CD, Lu M, Andersen SW, Pontecorvo MJ, Willis BA, et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes: the TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. 2022;79(10):1015–24.
doi: 10.1001/jamaneurol.2022.2793
pubmed: 36094645
pmcid: 9468959
Sims JR, Shcherbinin S, Lu M, Andersen SW, Sparks J, Evans CD, et al. TRAILBLAZER-ALZ study: dynamics of amyloid reduction after donanemab treatment. Alzheimer's Association International Conference; July 25–30; Denver, CO, USA; 2021.
Eisai’s Approach to U.S. pricing for Leqembi (LECANEMAB), a treatment for early Alzheimer’s disease, sets forth our concept of “Societal Value of Medicine” in relation to “Price of Medicine” maximizing value for all stakeholders while giving back value to society [press release]. Jan 7, 2023.
Institute for Clinical and Economic Review. Beta-Amyloid Antibodies for Early Alzheimer's Disease Draft Evidence Report. December 22, 2022.
Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US. JAMA Neurol. 2022;79(5):478–87.
doi: 10.1001/jamaneurol.2022.0315
pubmed: 35344024
pmcid: 8961406
Handels RLH, Green C, Gustavsson A, Herring WL, Winblad B, Wimo A, et al. Cost-effectiveness models for Alzheimer’s disease and related dementias: IPECAD modeling workshop cross-comparison challenge. Alzheimers Dement. 2023;19(5):1800–20.
doi: 10.1002/alz.12811
pubmed: 36284403
Lakdawalla DN, Phelps CE. A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE). Eur J Health Econ. 2022;23(3):433–51.
doi: 10.1007/s10198-021-01367-0
pubmed: 34495445
Lin P-J, Neumann PJ. Valuing Alzheimer disease therapies—considering costs and benefits beyond the patient. JAMA Netw Open. 2021;4(10):e2131913-e.
doi: 10.1001/jamanetworkopen.2021.31913
Ito K, Chapman R, Pearson SD, Tafazzoli A, Yaffe K, Gurwitz JH. Evaluation of the cost-effectiveness of drug treatment for Alzheimer disease in a simulation model that includes caregiver and societal factors. JAMA Netw Open. 2021;4(10): e2129392.
doi: 10.1001/jamanetworkopen.2021.29392
pubmed: 34677596
pmcid: 8536950
Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care-a health economics approach: an ISPOR Special Task Force Report [3]. Value Health. 2018;21(2):131–9.
doi: 10.1016/j.jval.2017.12.007
pubmed: 29477390
Neumann PJ, Garrison LP, Willke RJ. The history and future of the “ISPOR Value Flower”: addressing limitations of conventional cost-effectiveness analysis. Value Health. 2022;25(4):558–65.
doi: 10.1016/j.jval.2022.01.010
pubmed: 35279370
Centers for Medicare & Medicaid Services (CMS). Guiding an Improved Dementia Experience (GUIDE) Model 2023 [updated 4 August 2023]. Available from: https://www.cms.gov/priorities/innovation/innovation-models/guide . Accessed 18 Oct 2024.
Leong VW, Guerriere DN, Croxford R, Coyte PC. The magnitude, share and determinants of private costs incurred by clients (and their caregivers) of in-home publicly financed care. Healthc Policy. 2007;3(1):e141–59.
pubmed: 19305748
pmcid: 2645127
Belger M, Dell’Angelo G, Enstone A, Wyn R, Tockhorn-Heidenreich A. The impact of informal caregiving in Alzheimer’s disease dementia: a health utility study in the UK. Value Health. 2022;25(7):S545.
doi: 10.1016/j.jval.2022.04.1371